Targeted Therapy in Cancer Flashcards

1
Q

average age of diagnosis if chronic myeloid leukaemia

A

65

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

survival rate of CML at 5 years

A

60%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is chronic myeloid leukaemia

A

Cancer of bone marrow (myeloid cells)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

an AR signalling inhibitor that directly targets three stages of the AR

A

Enzalutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

3 angiogenesis stimulators

A

VEGF

FGF

PDGF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

main treatment of CML

A

Imatinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

how does imatinib work

A

drug which inhibits Abl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

3 drugs that inhibit angiogenesis

A

Sunitinib (‘Sutent’)

Pazopanib (‘Votrient’)

Axitinib (‘Inlyta’)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

3 problems with precision medication

A
  1. We don’t have a targeted drug for most patients
  2. Cancer isn’t usually a single mutation disease
  3. To understand the current tumour, we need to perform biopsies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

‘old fashioned’ cytotoxic drug working in many common tumours

A

Docetaxel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

side effect of Docetaxel

A

bone marrow suppression 


How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

first treatment for metastatic PC

A

Castration therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

drugs can’t target a specific process in an aberrant signalling pathway - true or false

A

false

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is personalised medicine

A

Targeting specific groups of patients using targeted therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Oncogenes (eg. Kinases) cause pathways to be

A

overactive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Tumour suppressor genes don’t work because they

A

are missing circuit components

17
Q

clonal

A

Some mutations were present throughout individual tumour

18
Q

subclonal

A

Some mutations only present in a subset of copies

19
Q

Advantages of newer targeted treatments

A

More selective for cancer cells

Less selective for normal cells

20
Q

in the stroma, which kinase results in renal cancer

A

VEGF receptor kinases

21
Q

in cancer cells, which mutation results in melanoma

A

Raf kinase mutations

MAP kinase

22
Q

in cancer cells, which mutation results in lung cancer

A

EGF receptor kinase mutations

ALK kinase mutations

23
Q

in cancer cells, which mutation results in gastro-intesinal stromal tumours

A

Kit kinase mutations

24
Q

in cancer cells, which mutation results in breast cancer

25
in cancer cells, which mutation results in medullary thyroid cancers
Ret kinase mutations
26
in cancer cells, which mutation results in myelodysplastic syndrome
JAK kinase mutations
27
how to tumours become desensitised to imatinib
Kinase mutations emerge which are no longer sensitive to imatinib
28
2 molecular markers in medicine
predictive markers prognostic markers
29
example of predictive marker
EGFR mutations in lung cancer
30
example of prognostic markers
CTCs in breast cancer
31
32
33
34
35
36